不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
我如何治疗移植后淋巴增殖性疾病
英文原题：How I treat posttransplant lymphoproliferative disorder.
查看英文原题
How I treat posttransplant lymphoproliferative disorder.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
移植后淋巴增殖性疾病（PTLD）是实体器官移植和造血干细胞移植（HSCT）后一种重要且可能危及生命的并发症。鉴于PTLD的异质性以及免疫抑制患者发生感染性并发症的风险，该疾病的治疗仍具有挑战性。单形性PTLD和B细胞来源的淋巴瘤占大多数病例。PTLD的治疗策略包括采用反应适应、风险分层的方法，使用减少免疫抑制、免疫治疗和/或化疗。采用这种方法，约25%的患者不需要化疗。高危患者或对一线治疗无应答的患者预后仍然很差，在这种情况下需要新的治疗方法。60%至80%的PTLD病例与Epstein-Barr病毒（EBV）感染相关，使得EBV导向治疗成为一种有吸引力的治疗方式。近年来，过继性免疫治疗的引入已成为难治性病例的一种有前景的选择；希望这些治疗策略将来能够用作更早线的治疗。
展开英文摘要原文
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). Given the heterogeneity of PTLD and the risk of infectious complications in patients with immunosuppression, the treatment of this disease remains challenging. Monomorphic PTLD and lymphoma of B-cell origin account for the majority of cases. Treatment strategies for PTLD consist of response-adapted, risk-stratified methods using immunosuppression reduction, immunotherapy, and/or chemotherapy.
With this approach, ∼25% of the patients do not need chemotherapy. Outcomes for patients with high risk or those who do not respond to frontline therapies remain dismal, and novel treatments are needed in this setting.
PTLD is associated with Epstein-Barr virus (EBV) infection in 60% to 80% of cases, making EBV-directed therapy an attractive treatment modality. Recently, the introduction of adoptive immunotherapies has become a promising option for refractory cases; hopefully, these treatment strategies can be used as earlier lines of therapy in the future.
论文信息
- 作者
- Amengual JE、Pro B
- 单位
- Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.United States
- 文献类型
- 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Blood2023 Oct 26
- 原文标识
- PubMed 37540819 · DOI 10.1182/blood.2023020075
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →